Caution/Monitor.cinacalcetfluvoxamine will increase the level or effect of cinacalcet by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.citalopramfluvoxamine will increase the level or effect of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongationclarithromycinfluvoxamine and clarithromycin both increase QTc interval. Modify Therapy/Monitor Closely.clobazamfluvoxamine will increase the level or effect of clobazam by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Dosage adjustment may be necessary ; CYP2C19 inhibitors may result in increased exposure to N-desmethylclobazam (active metabolite)clobazam will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. May be necessary to admininister lower doses of drugs metabolized by CYP2D6 when used concomitantlyclomipraminefluvoxamine and clomipramine both increase QTc interval. Modify Therapy/Monitor Closely.clonidinefluvoxamine, clonidine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. CNS derpressant effects enhanced.clopidogrelfluvoxamine will increase the level or effect of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SSRIs affect platelet activation; coadministration may increase risk of bleedingclozapinefluvoxamine will increase the level or effect of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.cobicistatfluvoxamine will increase the level or effect of cobicistat by Other (see comment). Use Caution/Monitor. Carfully titrate dose of antidepressant to desired effect, including using lowest feasible initial or maintenance dose , and monitor its response during coadministration with SSRIs and cobicistatcocaine topicalfluvoxamine and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.conivaptanfluvoxamine will increase the level or effect of conivaptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cortisonefluvoxamine will increase the level or effect of cortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cyclophosphamidefluvoxamine will increase the level or effect of cyclophosphamide by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.cyclosporinefluvoxamine will increase the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.cyproheptadinecyproheptadine decreases effects of fluvoxamine by pharmacodynamic antagonism. Use Caution/Monitor. May deminish serotonergic effect of SSRIs.daridorexantfluvoxamine will increase the level or effect of daridorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Daridorexant dose should not exceed 25 mg per night when coadministered with moderate CYP3A4 inhibitors.fluvoxamine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacinfluvoxamine will increase the level or effect of darifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.darunavirfluvoxamine will increase the level or effect of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinibfluvoxamine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.deferasiroxdeferasirox will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.defibrotidedefibrotide increases effects of fluvoxamine by Other (see comment). Use Caution/Monitor. Comment: Defibrotide may enhance effects of platelet inhibitors.deflazacortfluvoxamine will increase the level or effect of deflazacort by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease deflazacort dose by one-third of recommended dose if coadministered with moderate or strong CYP3A4 inhibitorsdegarelixdegarelix and fluvoxamine both increase QTc interval. Use Caution/Monitor.desipraminefluvoxamine and desipramine both increase QTc interval. Modify Therapy/Monitor Closely.desvenlafaxinedesvenlafaxine will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. With higher desvenlafaxine doses (eg, 400 mg) decrease CYP2D6 substrate dose by up to 50%; dose adjustment not necessary with desvenlafaxine doses <100mgdeutetrabenazinedeutetrabenazine and fluvoxamine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexfenfluraminefluvoxamine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.dextroamphetaminefluvoxamine and dextroamphetamine both decrease serotonin levels. Modify Therapy/Monitor Closely.dextroamphetamine transdermalfluvoxamine, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).diazepamfluvoxamine will increase the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.diazepam intranasalfluvoxamine will increase the level or effect of diazepam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May decrease rate of diazepam elimination, causing a decrease in diazepam elimnation, thereby increasing adverse reactions to diazepamdichlorphenamidedichlorphenamide and fluvoxamine both decrease serum potassium. Use Caution/Monitor.diclofenacfluvoxamine, diclofenac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.difelikefalindifelikefalin and fluvoxamine both increase sedation. Use Caution/Monitor.diflunisalfluvoxamine, diflunisal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.dihydroergotaminefluvoxamine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.dihydroergotamine intranasalfluvoxamine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.diltiazemfluvoxamine will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dofetilidefluvoxamine and dofetilide both increase QTc interval. Modify Therapy/Monitor Closely.dolasetronfluvoxamine and dolasetron both increase QTc interval. Use Caution/Monitor.donepezildonepezil and fluvoxamine both increase QTc interval. Use Caution/Monitor.edoxabanfluvoxamine will increase the level or effect of edoxaban by anticoagulation. Use Caution/Monitor. SSRIs affect platelet activation; coadministration may increase risk of bleedingefavirenzfluvoxamine will increase the level or effect of efavirenz by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.efavirenz and fluvoxamine both increase QTc interval. Use Caution/Monitor.eletriptanfluvoxamine and eletriptan both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustateliglustat will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations; consider reducing dosage of concomitant drug and titrate to clincal effecteltrombopagfluvoxamine will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.eluxadolinefluvoxamine will increase the level or effect of eluxadoline by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Use caution when coadministering with strong CYP1A2 inhibitors; Not studiedfluvoxamine will increase the level or effect of eluxadoline by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Use caution when coadministering with CYP2C19 inhibitors; not studiedelvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Caution with CYP2D6 substrates for which elevated plasma concentrations may cause life-threatening eventsepcoritamabepcoritamab, fluvoxamine. affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Epcoritamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .epinephrinefluvoxamine and epinephrine both increase QTc interval. Modify Therapy/Monitor Closely.epinephrine racemicfluvoxamine and epinephrine racemic both increase QTc interval. Modify Therapy/Monitor Closely.ergotaminefluvoxamine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.erlotinibfluvoxamine will increase the level or effect of erlotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin basefluvoxamine and erythromycin base both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin ethylsuccinatefluvoxamine and erythromycin ethylsuccinate both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin lactobionatefluvoxamine and erythromycin lactobionate both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin stearatefluvoxamine and erythromycin stearate both increase QTc interval. Modify Therapy/Monitor Closely.ethinylestradiolethinylestradiol will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.ethotoinfluvoxamine will increase the level or effect of ethotoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.etodolacfluvoxamine, etodolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.etravirinefluvoxamine will increase the level or effect of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.fedratinibfedratinib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of CYP2D6 substrates as necessaryfelodipinefluvoxamine will increase the level or effect of felodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fenbufenfluvoxamine, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.fenfluraminefluvoxamine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, fluvoxamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.fenoprofenfluvoxamine, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fesoterodinefluvoxamine will increase the level or effect of fesoterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fexinidazolefexinidazole will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.finerenonefluvoxamine will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or moderate CYP3A4 inhibitors. Adjust finererone dosage as needed.fingolimodfingolimod and fluvoxamine both increase QTc interval. Use Caution/Monitor.fish oil triglyceridesfish oil triglycerides will increase the level or effect of fluvoxamine by anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulantsflecainidefluvoxamine and flecainide both increase QTc interval. Use Caution/Monitor.flibanserinfluvoxamine will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. May increase risk of hypotension, syncope, and CNS depressionfluconazolefluvoxamine and fluconazole both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluvoxamine and fluphenazine both increase QTc interval. Use Caution/Monitor.flurbiprofenfluvoxamine, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor.fluvastatinfluvoxamine will increase the level or effect of fluvastatin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.fondaparinuxfluvoxamine will increase the level or effect of fondaparinux by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, which may increase bleeding risk when coadministered with anticoabulantsformoterolfluvoxamine and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.fosamprenavirfluvoxamine will increase the level or effect of fosamprenavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.foscarnetfluvoxamine and foscarnet both increase QTc interval. Use Caution/Monitor.fosphenytoinfluvoxamine will increase the level or effect of fosphenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.frovatriptanfluvoxamine and frovatriptan both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentinfluvoxamine, gabapentin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coaadministration with CNS depressant may result in fatal respiratory depression. Use lowest dose possible and monnitor for respiratory depression and sedation.gabapentin enacarbilfluvoxamine, gabapentin enacarbil. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coaadministration with CNS depressant may result in fatal respiratory depression. Use lowest dose possible and monnitor for respiratory depression and sedation.ganaxolonefluvoxamine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and fluvoxamine both increase QTc interval. Use Caution/Monitor.glofitamabglofitamab, fluvoxamine. affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Glofitamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .granisetrongranisetron and fluvoxamine both increase QTc interval. Use Caution/Monitor.grapefruitgrapefruit will increase the level or effect of fluvoxamine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.green teagreen tea, fluvoxamine. Either increases toxicity of the other by anticoagulation. Use Caution/Monitor.guanfacinefluvoxamine will increase the level or effect of guanfacine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If coadministered with extended release, reduce guanfacine dosage in half of recommended dose; specific recommendation for immediate release form not availablehaloperidolfluvoxamine and haloperidol both increase QTc interval. Modify Therapy/Monitor Closely.hydrocodonefluvoxamine and hydrocodone both increase serotonin levels. Use Caution/Monitor. If concomitant use warranted, carfully observe patient, particularly during treatment initiation and dose adjustmenthydroxyzinehydroxyzine and fluvoxamine both increase QTc interval. Use Caution/Monitor.ibrutinibibrutinib will increase the level or effect of fluvoxamine by anticoagulation. Use Caution/Monitor. Ibrutinib may increase risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleedingibuprofenfluvoxamine, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.ibuprofen IVfluvoxamine, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ifosfamidefluvoxamine will decrease the level or effect of ifosfamide by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. CYP2B6 inhibitors may decrease metabolism of ifosfamide to its active metabolite, potentially reducing ifosfamide therapeutic effectsiloperidonefluvoxamine and iloperidone both increase QTc interval. Use Caution/Monitor.imatinibimatinib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.imipraminefluvoxamine